Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Enter your email address below and subscribe to our newsletter

Scientists at the University of Waterloo have made a groundbreaking development in eye care technology by creating a new type of contact lens that not only serves as a protective bandage for corneal wounds but also delivers healing drugs in…

In a landmark study that promises new hope for nearly 1.5 million people worldwide suffering from retinitis pigmentosa (RP), scientists at Columbia University Vagelos College of Physicians and Surgeons are pioneering a gene therapy that could potentially treat RP patients…

In a recent phase II clinical trial conducted by the National Eye Institute (NEI), part of the National Institutes of Health, the antibiotic minocycline, known for its anti-inflammatory properties, was tested for its efficacy in slowing down the progression of…

Research teams at Purdue University’s College of Engineering have been awarded two grants from the National Eye Institute, totaling an impressive $6.7 million. These funds are earmarked for the development of specialized smart soft contact lenses designed for the continuous monitoring…

Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy of its novel nitric oxide-donating bimatoprost eye drop, NCX 470, against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma…

Innovent Biologics announced that its second Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection, has achieved its primary endpoint in treating Chinese subjects with neovascular age-related macular degeneration (nAMD).…

Eye color, a key trait that contributes to the uniqueness of an individual’s appearance, is determined by multiple genetic factors and can signify more than just aesthetic differences. It involves the complex interplay of genetics, melanin distribution in the iris,…

On March 8, Congress approved a partial government funding bill that introduces policies to mitigate reductions to the Medicare Physician Fee Schedule (MPFS), initially implemented on January 1. This new legislation decreases the cut from -3.37% to -1.69%, effective from…

As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…

In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…